GENFIT-ADR (GNFT) Stock Fundamental Analysis
USA - NASDAQ:GNFT - US3722791098 - ADR
4.065 USD
-0.04 (-1.09%)
3.82 USD
-0.25 (-6.03%)
Taking everything into account, GNFT scores 2 out of 10 in our fundamental rating. GNFT was compared to 531 industry peers in the Biotechnology industry. Both the profitability and financial health of GNFT have multiple concerns. GNFT is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year GNFT has reported negative net income.
In the past year GNFT has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: GNFT reported negative net income in multiple years.
In multiple years GNFT reported negative operating cash flow during the last 5 years.
1.2 Ratios
GNFT has a Return On Assets of -17.89%. This is in the better half of the industry: GNFT outperforms 78.15% of its industry peers.
GNFT has a Return On Equity (-73.87%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.89% | ||
| ROE | -73.87% | ||
| ROIC | N/A |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GNFT's Profit Margin has declined in the last couple of years.
In the last couple of years the Operating Margin of GNFT has declined.
GNFT has a Gross Margin of 95.42%. This is amongst the best in the industry. GNFT outperforms 94.73% of its industry peers.
In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
GNFT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.42% |
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
2. Health
2.1 Basic Checks
GNFT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GNFT has more shares outstanding
Compared to 5 years ago, GNFT has more shares outstanding
GNFT has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.52, we must say that GNFT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GNFT (-1.52) is comparable to the rest of the industry.
GNFT has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
GNFT has a worse Debt to Equity ratio (0.09) than 63.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.52 |
ROIC/WACCN/A
WACC7.15%
2.3 Liquidity
GNFT has a Current Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.74, GNFT is in line with its industry, outperforming 43.88% of the companies in the same industry.
A Quick Ratio of 3.74 indicates that GNFT has no problem at all paying its short term obligations.
GNFT has a Quick ratio of 3.74. This is comparable to the rest of the industry: GNFT outperforms 46.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 |
3. Growth
3.1 Past
The earnings per share for GNFT have decreased strongly by -327.32% in the last year.
Measured over the past years, GNFT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -70.77% on average per year.
Looking at the last year, GNFT shows a very negative growth in Revenue. The Revenue has decreased by -45.94% in the last year.
The Revenue has been growing by 11.61% on average over the past years. This is quite good.
EPS 1Y (TTM)-327.32%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-139.82%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-39.51%
3.2 Future
Based on estimates for the next years, GNFT will show a very negative growth in Earnings Per Share. The EPS will decrease by -29.44% on average per year.
Based on estimates for the next years, GNFT will show a decrease in Revenue. The Revenue will decrease by -1.86% on average per year.
EPS Next Y-110.7%
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%
EPS Next 5Y-29.44%
Revenue Next Year-8.28%
Revenue Next 2Y-21.93%
Revenue Next 3Y-9.85%
Revenue Next 5Y-1.86%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GNFT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNFT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as GNFT's earnings are expected to decrease with -45.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%
5. Dividend
5.1 Amount
GNFT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.065
-0.04 (-1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.76%
Inst Owner Change0%
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap203.26M
Revenue(TTM)45.41M
Net Income(TTM)-38.76M
Analysts90.77
Price Target10.41 (156.09%)
Short Float %0.05%
Short Ratio3.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.82%
PT rev (3m)-2.1%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-109.24%
EPS NY rev (3m)42.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.91%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.87 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.35 | ||
| P/tB | 82.63 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.89
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS1.05
BVpS1.21
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.89% | ||
| ROE | -73.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.42% | ||
| FCFM | N/A |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score2
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 188.46% | ||
| Cap/Sales | 7.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 | ||
| Altman-Z | -1.52 |
F-Score2
WACC7.15%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-327.32%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-139.82%
EPS Next Y-110.7%
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%
EPS Next 5Y-29.44%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-39.51%
Revenue Next Year-8.28%
Revenue Next 2Y-21.93%
Revenue Next 3Y-9.85%
Revenue Next 5Y-1.86%
EBIT growth 1Y-216.85%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year-6.17%
EBIT Next 3Y-0.9%
EBIT Next 5YN/A
FCF growth 1Y87.25%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y93.33%
OCF growth 3Y-46.21%
OCF growth 5YN/A
GENFIT-ADR / GNFT FAQ
What is the fundamental rating for GNFT stock?
ChartMill assigns a fundamental rating of 2 / 10 to GNFT.
Can you provide the valuation status for GENFIT-ADR?
ChartMill assigns a valuation rating of 0 / 10 to GENFIT-ADR (GNFT). This can be considered as Overvalued.
Can you provide the profitability details for GENFIT-ADR?
GENFIT-ADR (GNFT) has a profitability rating of 2 / 10.
Can you provide the financial health for GNFT stock?
The financial health rating of GENFIT-ADR (GNFT) is 3 / 10.